Xiangyan Qiu
Research Subjects
Xiangyan Qiu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jose Limuel Gutierrez
YS Biopharma (Philippines) Co. Ltd., Bonifacio Global City, Taguig, Philippines
2 shared publications - Renan James Lim
YS Biopharma (Philippines) Co. Ltd., Bonifacio Global City, Taguig, Philippines
2 shared publications - Robert Neil F. Leong
YS Biopharma (Philippines) Co. Ltd., Bonifacio Global City, Taguig, Philippines
2 shared publications - Yuan Liu
YS Biopharma (China) Co. Ltd., Beijing, China
2 shared publications - Zenaida Mojares
YS Biopharma (Singapore) Co. Ltd., Singapore, Singapore
2 shared publications - Ahmad Halima
PDC Contract Research Organization, Abu Dhabi, United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 329-337
Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study
Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):329-337. https://doi.org/10.7774/cevr.2024.13.4.329
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 329-337
Open AccessSafety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study
Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):329-337. https://doi.org/10.7774/cevr.2024.13.4.329
- Open Access
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 315-328
Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial
Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):315-328. https://doi.org/10.7774/cevr.2024.13.4.315
- 1 January 2024
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 13 (4) , 315-328
Open AccessSafety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial
Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):315-328. https://doi.org/10.7774/cevr.2024.13.4.315